Harris Reacts to Administration Halt on Insulin and EpiPen Cost Savings
WASHINGTON, DC: Congressman Andy Harris, M.D., issued the following statement after the Biden Administration halted a Trump era executive action that would lower consumer cost of insulin and EpiPens by requiring community health centers to pass on all discounts and savings from insulin and EpiPens to patients or risk losing access to federal grant dollars:
“Our community health centers in the First District play a crucial role in serving low income patients. The action taken by the Trump Administration to lower the out-of-pocket cost to consumers of insulin and EpiPens would have helped thousands of my constituents who use these medications – yet President Biden elected to halt this cost-saving tactic to ‘scrutinize Trump health policies.’ This policy didn’t need scrutiny, it needed implementation. This action by the incoming Biden Administration proves that they support large corporate interests over my hard-working constituents. I am ready and willing to work with the incoming administration on lowering prescription drug costs, but this first action on their part does nothing but help keep drug costs high.”
Maryland’s First Congressional District is served by 5 community health centers, with over 100,000 patients and millions of dollars in leveraged federal funding each year.